Acumen Pharmaceuticals (ABOS) Income from Non-Controlling Interests (2021 - 2026)
Acumen Pharmaceuticals (ABOS) reported Income from Non-Controlling Interests of -$62000.0 for Q1 2026, down 198.41% on a YoY basis from $63000.0 in Q1 2025, and down 138.46% sequentially from -$26000.0 in Q4 2025.
Acumen Pharmaceuticals (ABOS) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$62000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 198.41% year-over-year to -$62000.0; the trailing twelve-month figure through Mar 2026 stood at $6000.0 (down 96.23% YoY), and the FY2025 full-year result was $131000.0, up 136.39% from the prior year.
- Income from Non-Controlling Interests retreated to -$62000.0 in Q1 2026, from -$26000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $821000.0 in Q4 2023 to a low of -$583000.0 in Q1 2022.
- A 5-year average of $15750.0 and a median of -$6000.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 397.81% in 2024, while the deepest fall reached 300.88% in 2024.
- Tracing ABOS's Income from Non-Controlling Interests over 5 years: stood at $214000.0 in 2022, then surged by 283.64% to $821000.0 in 2023, then plunged by 168.94% to -$566000.0 in 2024, then jumped by 95.41% to -$26000.0 in 2025, then slumped by 138.46% to -$62000.0 in 2026.
- Business Quant data shows ABOS's Income from Non-Controlling Interests at -$62000.0 in Q1 2026, -$26000.0 in Q4 2025, and $86000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | - |
| 10 | Acumen Pharmaceuticals | 137.82 Mn | 137.82 Mn | - | -62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | -26,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | 63,000.00 |
| Dec 31, 2024 | -566,000.00 |
| Sep 30, 2024 | 682,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | -456,000.00 |
| Dec 31, 2023 | 821,000.00 |
| Sep 30, 2023 | 137,000.00 |
| Jun 30, 2023 | -122,000.00 |
| Mar 31, 2023 | 227,000.00 |
| Dec 31, 2022 | 214,000.00 |
| Jun 30, 2022 | -151,000.00 |
| Mar 31, 2022 | -583,000.00 |
| Dec 31, 2021 | -203,000.00 |
| Sep 30, 2021 | -28,000.00 |